<DOC>
	<DOCNO>NCT00002072</DOCNO>
	<brief_summary>To determine safety efficacy erythropoietin ( r-HUEPO ) administer AIDS patient anemia secondary disease and/or concomitant zidovudine ( AZT ) therapy .</brief_summary>
	<brief_title>A Double-Blind , Placebo-Controlled Study With Open-Label Follow-Up To Determine Safety Efficacy r-HuEPO AIDS Patients With Anemia Induced Their Disease AZT Therapy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Exclusion Criteria Coexisting Condition : Patients follow excluded : History primary hematologic disease . Clinically significant disease / dysfunction pulmonary , cardiovascular , endocrine , neurologic , gastrointestinal , genitourinary system attributable underlying AIDS . AIDSrelated dementia . Uncontrolled hypertension ( diastolic Blood Pressure &gt; 100 mmHg ) . Presence concomitant iron deficiency . Anemia attributable factor AIDS zidovudine ( AZT ) therapy . Acute opportunistic infection . History seizure . Patients clinically significant disease / dysfunction pulmonary , cardiovascular , endocrine , neurologic , gastrointestinal , genitourinary system attributable underlying AIDS exclude . Prior Medication : Excluded within 30 day study entry : Experimental drug experimental device . Cytotoxic chemotherapy . Excluded within 2 month study entry : Androgen therapy . Clinical diagnosis AIDS relate anemia . Clinical diagnosis AIDS . Clinically stable 1 month precede study entry . Substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 1989</verification_date>
	<keyword>Recombinant Proteins</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Anemia</keyword>
	<keyword>Zidovudine</keyword>
</DOC>